Kaplan Fox is Investigating Possible Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)

Fulcrum Therapeutics is facing a securities-violations investigation by Kaplan Fox & Kilsheimer while the company disclosed the discontinuation of its pociredir program for sickle cell disease due to FDA concerns about malignancy risk. The stock fell from a June 1, 2026 close of $6.42 to $3.14 on June 2, 2026, down $3.28 (-51.09%), after the FDA indicated PRC2-targeting drugs carry equivalent malignancy risk. The update materially worsens the company’s regulatory and clinical outlook, raising additional legal overhang for investors.

Analysis

The equity is now trading less like a biotech with pipeline optionality and more like a residual cash-and-control claim. The immediate market mechanism is not the plaintiff letter; it is the collapse of the lead asset’s partnering value and the higher probability of financing dilution if management has to fund a multi-year wind-down while defending litigation. In small-cap biotech, once the FDA story flips from delay to class-wide mechanism risk, the terminal value of the platform can re-rate faster than the lawsuit can ever be monetized.

Second-order, this is a negative read-through for any public PRC2/EZH2-type epigenetic strategy: investors will demand a higher probability haircut on the next program touching the same biology, even if the company insists on subunit differences. In sickle-cell, the loss of a lower-burden oral option subtly improves the relative positioning of curative gene-editing/gene-therapy approaches, but that benefit is mostly 6-18 month adoption and reimbursement work, not an immediate revenue transfer.

The key risk is that the stock stops falling once it approaches net cash, so chasing downside after a 50% gap is usually poor risk/reward unless runway is short or a dilutive raise is imminent. What can reverse the trend is a credible non-PRC2 asset sale/partnership, a balance sheet that comfortably funds the next 12-18 months, or a court dismissal that removes legal overhang; absent that, the near-term catalyst path is mostly complaints, financing risk, and guidance about remaining programs. The consensus is likely overweighting litigation economics and underweighting the fact that the real impairment is already fundamental, not legal.

Key Decisions for Investors

• Do not chase the first gap-down; if liquidity is sufficient, sell/short FULC only on any 10-20% relief rally over the next 1-3 weeks, with a stop above the post-event rebound high and a target anchored to cash-adjusted value rather than headline damages.
• Use the next 10-Q/earnings call as the real catalyst watchpoint: if cash runway falls below ~12 months or management signals a raise, that is the point to press the short; if runway is >18 months, cover part of the position because downside likely compresses toward liquidation value.
• Relative-value idea: long VRTX/CRSP as beneficiaries of sustained SCD modality preference, funded by short FULC only if you want a cleaner expression of the thesis that oral small-molecule substitution just weakened; otherwise avoid forcing the pair because the beta relationship is imperfect.
• Set an alert for any PRC2/EZH2 peer commentary or FDA class-effect language; if regulators broaden the malignancy concern, reduce exposure across the basket immediately because that would shift this from idiosyncratic failure to platform de-rating.